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Objectives. This study evaluated the diagnostic value of dipyr-
idamole plus low level treadmill exercise (dipyridamole stress)
thallium-201 single-photon emission computed tomography
(SPECT) in patients taking antianginal drugs.
Background. Dipyridamole stress is the major substitute for
maximal exercise in patients referred for myocardial perfusion
imaging. Although antianginal drugs are commonly suspended
before exercise, dipyridamole stress is usually performed without
discontinuing these drugs.
Methods. Twenty-six patients underwent two dipyridamole per-
fusion studies: the first without (SPECT-1) and the second with
(SPECT-2) antianginal treatment. Twenty-one patients (81%)
received calcium antagonists, 19 (73%) received nitrates, and 8
(31%) received beta-blockers. Eighteen of the patients underwent
coronary angiography. Data are presented as the mean value 6
SD.
Results. Visual scoring yielded significantly larger and more
severe reversible perfusion defects for SPECT-1 than for
SPECT-2. Quantitative analysis showed larger perfusion defects
on stress images of SPECT-1 in the left anterior descending
coronary artery (LAD) (25 6 21% vs. 17 6 15%, p 5 0.003), left
circumflex coronary artery (LCx) (56 6 35% vs. 48 6 36%, p 5
0.03) and right coronary artery (RCA) (36 6 27% vs. 25 6 24%,
p 5 0.008) territories. Individual vessel sensitivities in the LAD,
LCx and RCA territories were 93%, 79% and 100% for SPECT-1
and 64%, 50% and 70% for SPECT-2, respectively. These differ-
ences were highly significant for the LAD (p 5 0.004) and LCx
(p 5 0.00004) territories. The overall individual vessel sensitivity
of SPECT-1 was significantly higher than that of SPECT-2 (92%
vs. 62%, p 5 0.000003). Specificity was not significantly different
in SPECT-1 compared with SPECT-2 (80% and 93%, p 5 0.33).
Conclusions. Continued use of antianginal drugs before dipyr-
idamole plus low level treadmill exercise thallium-201 SPECT
may reduce the extent and severity of myocardial perfusion
defects, resulting in underestimation of coronary artery disease.
(J Am Coll Cardiol 1998;31:1540–6)
©1998 by the American College of Cardiology
Pharmacologic vasodilation with dipyridamole in conjunction
with low level treadmill exercise (dipyridamole stress) is a
substitute for maximal exercise in patients undergoing myocar-
dial perfusion imaging who are unable to exercise adequately
(1). Antianginal medications are usually discontinued before
exercise myocardial perfusion imaging because they may reduce
the sensitivity and negative predictive value of the test (2–6).
Standard protocols for dipyridamole stress perfusion imaging,
however, do not require discontinuation of antianginal drugs.
Furthermore, reluctance to discontinue these drugs, especially
in patients with significant angina or hypertension, is a fre-
quent reason for performing a pharmacologic stress test. Intra-
venous dipyridamole induces maximal vasodilation and in-
creases regional heterogeneity in myocardial perfusion in the
presence of coronary artery disease (CAD), as detected by
myocardial perfusion imaging (7–13). Antianginal drugs may
interfere with this mechanism and reduce the accuracy of the
test.
The goal of the present study was to assess the effect of
antianginal drugs on the diagnostic yield of thallium-201
single-photon emission computed tomographic (SPECT) im-
aging in patients with CAD after dipyridamole combined with
low level treadmill exercise. This was achieved by comparing
the results of two separate dipyridamole stress tests, each
performed according to standard protocol and carried out in
the same group of patients. The only difference between the
two studies was that patients stopped taking their antianginal
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drugs before the first test but did not discontinue these drugs
before the second test.
Methods
Patient group and study design. Twelve hundred patients
underwent dipyridamole stress thallium-201 SPECT in our
laboratory between June 1995 and January 1997. According to
our routine protocol, patients were not asked to discontinue
antianginal medications before the test. Twenty-six patients
with one or more reversible perfusion defects, who on their
own initiative discontinued antianginal treatment before the
dipyridamole SPECT study (SPECT-1), formed the present
study group. Only patients who were not taking beta-blockers
for at least 48 h, nitrates for at least 24 h and calcium
antagonists for at least 48 h before the study were included.
These patients were asked to return for a repeat dipyridamole
stress SPECT study (SPECT-2), without discontinuing their
antianginal treatment. The mean time interval between
SPECT-1 and SPECT-2 was 11 6 6 days (range 6 to 24).
Patients were excluded if they had complete left bundle branch
block, a permanent pacemaker or suspected left main CAD.
Dipyridamole stress and imaging protocols. The stress and
imaging protocols of the test were identical for SPECT-1 and
SPECT-2. Caffeinated beverages were not allowed for 24 h
before both dipyridamole studies. A dose of 0.56 mg/kg body
weight of dipyridamole was infused over a 4-min period,
followed by a submaximal treadmill exercise. Four minutes
after completion of dipyridamole infusion, a bolus of 2.5 to 3
mCi of thallium-201 was injected intravenously and exercise
was continued for 1 min. Continuous electrocardiographic
(ECG) monitoring was carried out, and blood pressure was
measured and a 12-lead ECG obtained at baseline and every
2 min throughout the test. The clinical response was consid-
ered positive if the patient’s angina was reproduced. Horizon-
tal or downsloping ST segment depression $1 mm or upslop-
ing ST segment depression $1.5 mm at 0.08 s after the J point
was considered as an ischemic ECG response. A dose of
100 mg of aminophylline was administered intravenously in the
event of chest pain or other symptoms, or after significant ST
segment depression. SPECT acquisition was started ;8 min
after thallium-201 injection. Imaging was performed with
either a single-detector (SP4, Elscint Ltd., Israel) or right-
angled dual-detector camera (CardiaL, Elscint Ltd., Israel),
with a high resolution, parallel-hole collimator. The same
camera was used for each patient in the SPECT-1 and
SPECT-2 studies. A 20% window centered on the 70-keV
photopeaks and a 10% window centered on the 167-keV
photopeaks were used. Thirty projections of 40 s each were
obtained over a 180° arc in a circular orbit (from the 45° right
anterior oblique to the 45° left posterior oblique projection).
After termination of SPECT imaging, reinjection of 1 mCi of
thallium-201 was administered. Redistribution images were
obtained 3.5 to 4 h after dipyridamole infusion. After acquisi-
tion, all studies were subjected to quality control (14), includ-
ing cine display of the raw data, which enabled the detection of
cardiac motion and its correction if necessary.
Coronary angiography. Eighteen of the 26 patients were
referred for coronary angiography by the attending physician
according to clinical indications. The mean time interval
between the SPECT-1 study and coronary angiography was
39 6 53 days (range 23 to 161). There were no intervening
coronary events or therapeutic interventions during this pe-
riod.
Coronary angiograms were obtained in multiple projections
and evaluated by an independent, experienced angiographer.
The degree of stenosis of the coronary arteries was visually
estimated as a percentage of the normal segment preceding the
stenosis. Significant coronary stenosis was defined as .50%
narrowing of the lumen diameter in a coronary artery or one of
its major branches. Three of the 18 patients had undergone
coronary artery bypass graft surgery in the past. In these
patients significant coronary stenosis was defined as .50%
narrowing of the lumen diameter of a native coronary artery,
combined with significant narrowing (.50%) of the graft
connected to that artery. All patients had significant narrowing
of at least one coronary artery. The number of patients with
single-, double- and triple-vessel disease was 4 (22.2%), 8
(44.4%) and 6 (33.3%), respectively.
Data analysis. Visual analysis. The 52 SPECT studies were
visually assessed at random by an experienced nuclear cardi-
ologist who had no knowledge of the clinical and angiographic
data. The 20-segment model of the left ventricle was used;
three representative short-axis slices from the apical, mid and
basal portions of the left ventricle were each divided into six
segments, and the apical portion of one representative vertical
long-axis slice was divided into two segments, as previously
described (15). Each segment was scored using a 5-point
scoring system: 0 5 normal; 1 5 mildly reduced; 2 5 moder-
ately reduced; 3 5 severely reduced; and 4 5 absence of
thallium-201 uptake. A total of 520 segments were analyzed.
The following indexes were calculated for each SPECT
study: 1) summed stress score (SSS) 5 the sum of stress scores
of all 20 segments; 2) summed redistribution score (SRS) 5
the sum of the differences between stress and rest score of each
segment (differences ,2 were not included); 3) percentage of
segments with a score .1 (extent of perfusion defects); and 4)
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
LAD 5 left anterior descending coronary artery
LCx 5 left circumflex coronary artery
RCA 5 right coronary artery
SPECT 5 single-photon emission computed tomography
(tomographic)
SRS 5 summed redistribution score
SSS 5 summed stress score
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percentage of segments with a score .2 (severity of perfusion
defects).
Quantitative analysis. The location and size of perfusion
defects at stress and redistribution were quantitatively assessed
using a polar map display of a commercially available software
program previously described (16,17). Defects were assigned
to one of the three coronary artery territories, and expressed as
a percentage of that territory.
Statistical analysis. All data are expressed as the mean
value 6 SD. A comparison between SPECT-1 and SPECT-2
variables was performed using the two-tailed paired t test.
Distribution of segments according to visual score was com-
pared by using the kappa statistic with 95% confidence interval
(CI). In addition, the differences between quantitative stress
scores of SPECT-1 and SPECT-2 were analyzed by multiple
analysis of variance with repeated measures using the patient
as the unit of analysis and the percent score in each coronary
artery territory as the outcome variable, with Bonferroni
correction for multiple comparisons. These calculations were
performed using SPSS version 6.1 for Windows. Sensitivity and
specificity for detection of CAD were calculated for individual
vascular territories: sensitivity (%) 5 true positive/(true posi-
tive 1 false negative) 3 100; specificity (%) 5 true negative/
(true negative 1 false positive) 3 100. Sensitivities and spec-
ificities were compared by using the chi-square test. A p value
,0.05 was considered significant.
Results
Baseline clinical characteristics. The mean age of the 26
patients included in the study was 64 6 10 years (range 47 to
85); 24 (92%) were men and 2 (8%) were women. Twelve
(46%) had a previous myocardial infarction, 7 (27%) had
remote percutaneous coronary angiography and 6 (23%) had
coronary artery bypass graft surgery. Twenty-one patients
(81%) were treated with calcium channel blockers, 19 (73%)
with nitrates and only 8 (31%) with a beta-blocker. Twenty
patients (77%) received a combination of more than one drug.
Nitrates and calcium antagonists were the most frequent
combination (n 5 13). Seven of the eight patients taking
beta-blockers also received an oral nitrate, calcium antagonist
or both.
Clinical response and ECG and hemodynamic changes
during stress test. An ischemic clinical response was present
in 16 patients (62%) during the SPECT-1 study and in 10
patients (38%) during SPECT-2 (p 5 NS). Thus, 6 (37%) of 16
patients with a positive clinical response during SPECT-1
reverted to a negative response at SPECT-2. The SSS in these
six patients was 30 6 7 during SPECT-1 and 18 6 9 during
SPECT-2 (p 5 0.04). This difference was larger than that for
the whole study group (24 6 10 vs. 19 6 11). No patient with
anginal pain during the SPECT-2 study was asymptomatic
during SPECT-1. An ischemic ECG response was observed in
nine patients (35%) in both SPECT studies. Thus, the reduc-
tion in severity of perfusion defects in SPECT-2 was accom-
panied by a reduction in the frequency of anginal pain, but not
by a reduction in the frequency of ECG ischemia.
Baseline heart rate was similar during the SPECT-1 and
SPECT-2 studies (78 6 15 vs. 72 6 17 beats/min, p 5 0.11).
Baseline systolic and diastolic blood pressures were signifi-
cantly lower during SPECT-2 than during SPECT-1 (132 6 19
vs. 145 6 22 mm Hg, p 5 0.003 and 77 6 10 vs. 83 6
12 mm Hg, p 5 0.005, respectively). Changes in heart rate,
systolic blood pressure and rate–pressure product during di-
pyridamole plus submaximal exercise were similar in both
studies (45 6 19% vs. 43 6 24%, 22 6 13% vs. 3 6 21% and
43 6 32% vs. 50 6 47%, respectively; p 5 NS).
SPECT imaging. Visual analysis. Table 1 shows the results
of visual analysis of stress images. The number of segments is
displayed according to the visual score during SPECT-1 and
SPECT-2. Of the 520 segments analyzed, only 294 (57%)
showed exact score agreement. The kappa value was 0.36 (95%
CI 0.30 to 0.42). A higher score was present in 158 segments
(30%) during SPECT-1 as compared with only 68 segments
(13%) during SPECT-2 (p , 0.0001).
The mean SSS and mean SRS were both significantly higher
during the SPECT-1 study than during SPECT-2 (24 6 10 vs.
19 6 11, p 5 0.01 and 15 6 8 vs. 11 6 9, p 5 0.04 respectively
(Table 2). The proportion of segments with a score .1 and a
score .2, representing the extent and severity of perfusion
defects, respectively, were both larger during SPECT-1 than
during SPECT-2 (38% vs. 30% and 22% vs. 13%, p , 0.01).
Table 1. Segment Distribution According to Visual Score of Stress
Images During Single-Photon Emission Computed Tomography
With and Without Antianginal Therapy
Score for
SPECT-2
Score for SPECT-1
0 1 2 3 4
0 204 32 28 18 1
1 22 26 20 11 1
2 13 12 29 30 5
3 3 6 5 21 12
4 3 0 3 14
Exact agreement 57% (294 of 520 segments); kappa 0.36. Numbers in
boldface indicate exact agreement between SPECT-1 and SPECT-2. SPECT-1
and SPECT-2 5 dipyridamole stress thallium-201 single-photon emission com-
puted tomographic study with and without antianginal drugs, respectively.
Table 2. Results of Visual Analysis Indexes
SPECT-1 SPECT-2 p Value
SSS 24 6 10 19 6 11 0.01
SRS 15 6 8 11 6 9 0.04
No. of segments at
stress images with
Score .1 (extent) 198 (38%) 157 (30%) 0.007
Score .2 (severity) 116 (22%) 68 (13%) 0.00009
Data are presented as mean value 6 SD or number (%) of segments. SRS 5
summed redistribution score; SSS 5 summed stress score; other abbreviations as
in Table 1.
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Quantitative analysis. Table 3 shows the defect size at stress
and rest according to the coronary artery territory. The mean
overall stress score for SPECT-2 was significantly lower than
that for SPECT-1, by 11.1% (95% CI 5.7 to 16.5%) (p ,
0.0003). The mean size of perfusion defects at stress was
significantly larger for SPECT-1 than for SPECT-2 in the left
anterior descending coronary artery (LAD) (25 6 21% vs.
17 6 15%, p 5 0.003), left circumflex coronary artery (LCx)
(56 6 35% vs. 48 6 36%, p 5 0.03) and right coronary artery
(RCA) (36 6 27% vs. 25 6 24%, p 5 0.008) territories. The
differences in scores for the LAD and RCA territories re-
mained statistically significant (p 5 0.01 and p 5 0.02, respec-
tively) after the Bonferroni correction for multiple compari-
sons. For the LCx territory, the p value was 0.07.
The defect size was larger during SPECT-1 in 20 patients
(77%) in the LAD, 16 patients (62%) in the LCx and 17
patients (65%) in the RCA territories (Fig. 1). There were no
significant differences in the defect size at rest.
Detection of coronary stenosis in individual vessel terri-
tory. Coronary angiography demonstrated that 14 patients
had LAD stenosis, 14 patients had LCx stenosis and 11 patients
had RCA stenosis. Based on visual scoring with the assignment
of segments to individual coronary artery territories, SPECT-1
showed ischemia in the LAD territory in 13 patients, in the
LCx territory in 11 and in the RCA territory in 11. SPECT-2
showed ischemia in the LAD in 9 patients, in the LCx in 7
patients and in the RCA territory in 8 patients. Thus, of the 18
patients who underwent coronary angiography, the sensitivities
for detecting CAD in the LAD, LCx and RCA territories were
93%, 79% and 100%, respectively, for SPECT-1 as compared
with 64%, 50% and 70% for SPECT-2 (Fig. 2). These differ-
ences were statistically significant in the LAD (p 5 0.004) and
LCx (p 5 0.00004) regions, although the difference in the RCA
territory was not significant (p 5 0.15). Sensitivity to detect
CAD in any of the coronary vascular territories was signifi-
cantly higher in SPECT-1 as compared with SPECT-2 (92% vs.
62%, p 5 0.000003). Overall individual vessel specificity of
SPECT-1 and SPECT-2 was not significantly different (80%
and 93%, p 5 0.33).
Of the 18 patients who underwent coronary angiography,
underestimation of the number of coronary territories involved
was observed in 3 patients (17%) in SPECT-1 as compared
with 10 patients (56%) in SPECT-2 (p 5 0.03). The three
patients with underestimation of the number of stenosed
vessels in SPECT-1 had angiographic three-vessel disease,
which was underestimated as two-vessel disease, but still
showed a significant amount of ischemia. Of the 10 patients
with underestimation of the number of stenosed vessels in
SPECT-2, 8 (44%) had multivessel disease. These patients had
a significant amount of ischemia in SPECT-1 as compared with
a small amount of ischemia in SPECT-2, which would have led
to deferring angiography.
The case example in Figure 3 shows underestimation of
both the number of coronary arteries involved and the severity
of CAD in a patient with multivessel disease (moderate
mid-LAD stenosis and total occlusion of the proximal RCA
and mid-LCx, with collateral flow to both arteries from the
LAD), as demonstrated by angiography.
Table 3. Quantitative Analysis: Mean Defect Size (percent coronary artery territory at stress and rest imaging)
LAD LCx RCA
SPECT-1 SPECT-2
p
Value SPECT-1 SPECT-2
p
Value SPECT-1 SPECT-2
p
Value
Stress 25 6 21% 17 6 15% 0.003 56 6 35% 48 6 36% 0.03 36 6 27% 25 6 24% 0.008
Rest 13 6 11% 11 6 10% 0.3 35 6 32% 34 6 29% 0.8 21 6 20% 14 6 14% 0.08
Data are presented as mean value 6 SD. LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary artery;
other abbreviations as in Table 1.
Figure 1. Quantitative stress defect size in the three coronary artery
territories for individual patients without (SPECT-1) and with
(SPECT-2) antianginal drugs.
Figure 2. Sensitivities for the detection of single-vessel CAD without
(SPECT-1) and with (SPECT-2) antianginal drugs. Solid bars 5
SPECT2-1; open bars 5 SPECT-2.
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Discussion
This study evaluated the effect of antianginal drugs on
myocardial perfusion imaging after pharmacologic vasodila-
tion with dipyridamole in patients with CAD. The results show
that antianginal drugs reduce the extent and severity of
thallium-201 tomographic perfusion defects. Discontinuation
of antianginal drugs before the test resulted in improved
sensitivity for CAD detection in the individual vascular terri-
tories.
Effect of antianginal drugs on perfusion defects. Visual
and quantitative analyses of SPECT images showed concor-
dant results regarding the extent of perfusion defects at stress.
Discontinuation of antianginal drugs resulted in significantly
larger perfusion defects in all coronary artery territories. The
severity of perfusion defects at stress was also increased, as
confirmed by visual analysis. These differences in myocardial
perfusion at stress can be attributed to reversible defects,
because analysis of redistribution images yielded no difference
in the defect size at rest, and to higher reversibility scores when
antianginal drugs were discontinued.
Effect of antianginal drugs on individual vessel sensitivity.
Several investigators have evaluated the sensitivity of myocar-
dial perfusion imaging during pharmacologic vasodilation with
dipyridamole or adenosine for detection of individual CAD
(18–20). In these studies patients were not instructed to
discontinue antianginal drugs; therefore, variable proportions
of patients were taking these drugs at the time of the test.
Although overall sensitivity to detect CAD ranged from 87%
to 92%, individual vessel sensitivities were lower, in the range
of 50% to 80%. Our results show higher overall individual
vessel sensitivity for SPECT-1 as compared with SPECT-2
(92% vs. 62%, p 5 0.000003). Compared with previous reports,
sensitivities for SPECT-1 are higher, whereas sensitivities for
SPECT-2 are in the lower range of reported values. Recently,
Sundereswaran et al. (21) demonstrated that antianginal drugs
reduce the sensitivity of adenosine SPECT myocardial perfu-
sion imaging for detection of CAD. They compared test
sensitivity in two separate patient groups—one group taking and
the other not taking antianginal drugs. In the present study we
compared the results of dipyridamole SPECT myocardial
perfusion imaging performed with and without drug adminis-
tration in the same patient. Our results are concordant with the
results reported by Sundereswaran et al.
Effect of antianginal drugs on clinical and ECG responses.
There was no difference in the prevalence of either the ECG
ischemic response between SPECT-1 and SPECT-2, despite
the differences between these groups in the severity of perfu-
sion defects, or the clinical ischemic response. This may be due
to the low sensitivity of the ECG during dipyridamole stress.
Mechanism of influence of antianginal drugs on dipyrida-
mole perfusion imaging combined with submaximal exercise.
Antianginal drugs may lead to underestimation of CAD, as
evaluated by myocardial perfusion imaging after dipyridamole
plus submaximal exercise, through several mechanisms, one of
which is a reduction of the exercise level achieved. This
mechanism, however, seems unlikely because dipyridamole
combined with low level exercise (peak HR ,80% of predicted
value for age) demonstrated a negative predictive value and
sensitivity for detection of CAD, comparable to exercise
(22–29). Moreover, the fact that changes in HR, BP and
rate–pressure product in the present study were similar in
SPECT-1 and SPECT-2 implies that the level of hemodynamic
stress was similar in the two perfusion studies. Therefore, the
main mechanism responsible for reducing the size and severity
of reversible perfusion defects by antianginal drugs was prob-
ably not due to changes in oxygen consumption during the
treadmill exercise after dipyridamole injection. Most patients
in our study were taking nitrates (73%), calcium antagonists
(81%) or a combination of these, and only 8 patients (31%)
were taking beta-blockers at the time of SPECT-2. Indeed,
there was no significant difference in baseline HR in the two
dipyridamole studies, although baseline BP was lower during
SPECT-2.
Interference with the acute hyperemic response and redis-
tribution of blood flow induced by dipyridamole is a possible
mechanism by which antianginal coronary vasodilators such as
nitrates and calcium antagonists may influence myocardial
perfusion imaging after dipyridamole administration. In exper-
Figure 3. A, Horizontal short-axis slices and
polar maps of dipyridamole stress thallium-201
SPECT perfusion images from a 64-year old
man with a history of inferolateral myocardial
infarction and atypical angina. Antianginal
drugs were discontinued 48 h before the test.
Perfusion images show reversible defects in the
RCA, LCx and apical regions and a small
inferolateral nonreversible defect. B, Dipyrida-
mole SPECT perfusion images from the same
patient, performed without discontinuation of
antianginal drugs (isosorbide mononitrate and
metoprolol), showing a small, partially revers-
ible defect in the LCx territory.
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imental studies, Fam and McGregor (30,31) reported that
nitroglycerin reduced coronary vascular resistance of large
epicardial arteries, whereas dipyridamole reduced the resis-
tance of distal (resistive) arteries. Other studies (32,33) dem-
onstrated that dipyridamole induced a significant increase in
coronary flow of normally perfused myocardium, coupled with
a reduced flow reserve in the area supplied by a stenotic
coronary artery, resulting in inhomogeneity of regional myo-
cardial perfusion. In addition, transmural coronary steal of
blood flow from subendocardial to subepicardial regions oc-
curred owing to an absolute decrease of subendocardial flow in
the stenotic artery region (34–36). In contrast, nitroglycerin
has been shown to increase flow to ischemic myocardium,
while maintaining nonischemic flow (30,36–39). The endocar-
dial to epicardial flow ratio increased during intravenous
nitroglycerin infusion. These influences of nitrates on regional
blood flow in the presence of occlusive coronary disease are
the consequence of vasodilation of large conductance coronary
arteries, coronary collateral vessels and atherosclerotic steno-
ses (40–43) and are responsible for the angina-relieving effect
of nitrates. Another mechanism whereby nitrates might inter-
fere with the action of dipyridamole is the reduction of left
ventricular volume secondary to decreased venous return
(44,45), resulting in decreased myocardial oxygen consumption
(46) and improved subendocardial blood flow.
Calcium antagonists exert a direct vasodilatory effect on
large epicardial vessels as well as resistance vessels and in-
crease blood flow to normal myocardium as well as ischemic
myocardium (42,43). These counteracting effects of antianginal
drugs (nitrates and calcium antagonists), on the one hand, and
dipyridamole, on the other, may explain the underestimation
of CAD demonstrated in the present study.
Study limitations. The small number and heterogeneity of
the patients included in this study were partially compensated
for by the fact that all patients underwent two imaging tests
(with and without antianginal drugs), thereby strengthening
the statistical power of the study. The possibility of patients
consuming caffeinated beverages against our instruction, and
thereby potentially confounding the differences between the
results of SPECT-1 and SPECT-2, cannot be excluded because
blood caffeine levels were not compared. However, before
each test each patient was routinely asked about possible
caffeine consumption. In addition, there was only one habitual
coffee drinker of the 10 patients, with the largest differences
between the two studies, making this an unlikely potential
confounder.
Conclusions. We demonstrated that continuation of anti-
anginal therapy up to the day of the dipyridamole thallium-201
SPECT myocardial perfusion imaging test may cause underes-
timation of the magnitude of CAD. The fact that previous
administration of various antianginal drugs may lead to under-
estimation of both the size and severity of ischemia, as well as
to decreased sensitivity of this test for detecting multivessel
disease, should be taken into consideration by the clinician.
Moreover, the question whether reduced ischemia in pa-
tients taking a specific group of antianginal drugs represents a
“technical” underestimation or a preventive therapeutic effect
of these drugs remains to be answered. Further investigation is
required to assess the role of each individual drug group on
dipyridamole thallium-201 myocardial perfusion imaging.
Meanwhile, unless contraindicated, we recommend discontinu-
ing these drugs before the test.
We thank Vivienne York for editorial help in the preparation of this report.
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